Biomanufacturing capacity Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines biomanufacturing capacity, meaning the shared pilot, demonstration and contract fermentation capacity that lets developers move a biological process from the laboratory to commercial production. It tests how quickly the gap in pilot and demonstration capacity in the United States and Europe closes, and which participants capture value among facility operators, platforms, equipment suppliers and governments.

The gap is acknowledged by the organisations building the response. BioMADE has described the United States as severely lacking in pilot and demonstration scale equipment for precision fermentation, and a US Department of Defense investment of at least USD 80 million is converting a site in Hayward, California into a shared facility with tanks of up to 4,000 litres. Further sites near Ames, Iowa and in Minnesota are planned, with openings expected in 2028. The conclusion is that public money is now paying for capacity that private developers could not finance alone.

Funding continues to flow into the network. In April 2026 the Department of Defense and the National Science Foundation directed USD 21.4 million to 14 projects led by 23 member organisations of BioMADE, which now has 92 projects. Members match federal funding dollar for dollar. The conclusion is that capacity and the projects that use it are being built together, which supports early utilisation.

Europe is adding capacity through operators. Acies Bio, in Kamnik, Slovenia, reported in April 2026 that construction of a 30 cubic metre production fermentor is on schedule, with commissioning planned for the fourth quarter of 2026, after a 6.5 cubic metre addition in 2021. The conclusion is that European capacity grows in steps of single large tanks, and each addition opens scale-up options for developers.

The brief treats biomanufacturing capacity as a high-impact signal with a ten year horizon to 2036. It identifies which capacity types, regions and operators scale first and what each means for operators, developers, equipment suppliers and governments. It is a focused 110-page decision brief that presents an indicative trajectory rather than a segmented market model.

Biomanufacturing capacity is the tank volume, aeration, downstream processing and analytical capability that developers rent to run fermentation at pilot, demonstration and commercial scale.

Pilot scale runs in tanks of a few thousand litres to test a process. Demonstration scale runs in tanks of about 10,000 to 25,000 litres to prove cost and quality. Commercial scale runs far larger tanks.

The Hayward site shows the model: stirred and aerated tanks of up to 4,000 litres, with harvest tanks, centrifuges, membrane filtration, evaporation and spray drying alongside.

Uses are specialty chemicals, food ingredients, materials and other bio-based products that need scale-up before commercial plants are financed.

The limits are the cost and build time of facilities, access to downstream equipment and the risk that early customers fail before capacity is full. The period turns on how fast funded sites open and fill.

The biomanufacturing capacity market, covering shared pilot, demonstration and contract fermentation capacity for industrial, food and materials products in the United States and Europe, and excluding in-house capacity of producers, biopharmaceutical manufacturing and chemical plants, is valued at USD 4–6 billion in 2026 and is projected to reach USD 13.58–20.37 billion by 2036, at a CAGR of 13%.

The 2026 base rests on contract and shared pilot and demonstration fermentation capacity used by developers, with new public funded sites opening from 2026 and demonstration sites from 2028. Growth then follows the opening of these sites and the move of successful processes to commercial scale.

The forecast is sensitive to the pace of facility construction, public funding and utilisation. Regionally, the United States carries the larger funded programme and Europe adds capacity through operators, with the two together defining the market.

The base case assumes funded pilot sites open from 2026, demonstration sites open by 2028 and bookings reach commercial levels by 2030. An accelerated case assumes sites open earlier and fill quickly, bringing the inflection to 2028 and lifting the 2036 value to the top of the range. A delayed case assumes construction slips and early customers fail, holding growth at the bottom of the range.

Growth drivers

• Shortage of scale-up capacity.
• Defence and industrial funding.
• Demand from developers of bio-based products.
• Supply chain security.

Enablers

• Consortium and federal funding.
• Conversion of existing pilot sites.
• Equipment suppliers.
• University partnerships.

Restraints and barriers

• Capital intensity of facilities.
• Long build times.
• Failure of early customers.
• Utilisation risk.

The direction of biomanufacturing capacity is set by the gap in pilot and demonstration capacity, government security and industrial policy, demand from developers, consortium funding, and the capital intensity of facilities.

The key participants in biomanufacturing capacity include Ginkgo Bioworks Holdings, Inc., Lygos, Inc., Liberation Labs, Inc., Solugen, Inc., Synonym Bio, Inc., Culture Biosciences, Inc., Acies Bio d.o.o., Novonesis A/S, DSM-Firmenich AG, Cargill, Incorporated, BASF SE, Evonik Industries AG, Lonza Group AG, Thermo Fisher Scientific Inc., Sartorius AG, GEA Group Aktiengesellschaft, Bio Base Europe Pilot Plant vzw, Fermentationexperts A/S, Perfect Day, Inc., Pow.bio, Inc., MycoTechnology, Inc., Upside Foods, Inc., BioMADE, Iowa State University, Wageningen University & Research, Technical University of Denmark, Delft University of Technology, Imperial College London, ETH Zurich, National Renewable Energy Laboratory, Lawrence Berkeley National Laboratory, U.S. Department of Defense, National Science Foundation, U.S. Department of Energy, European Commission, European Investment Bank, National Security Commission on Emerging Biotechnology, Good Food Institute, Biotechnology Innovation Organization and EuropaBio.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as capacity grows.

BioMADE, Lygos and Liberation Labs lead on shared facilities in the United States, Acies Bio and Bio Base Europe Pilot Plant lead in Europe, and GEA, Sartorius and Thermo Fisher Scientific lead on equipment. Competitive intensity is low in demonstration scale capacity and moderate in pilot scale.

Where value migrates.

In 2026 value sits with owners of scarce pilot capacity, because developers wait for tank time and funded sites are only starting to open. By 2031 it moves toward operators of demonstration scale capacity, because proven processes need larger tanks before commercial plants are financed. By 2036 it settles in integrated platforms that combine design, scale-up and manufacturing. Margins hold for operators with high utilisation and downstream equipment and narrow for those with idle tanks.

The signals converge on a shortage that public money is starting to close. Defence funded sites, project awards to 14 projects and new tank capacity in Europe support growth, while the cost of facilities, long build times and utilisation risk limit the pace.

Structural limits show where progress could slow: the capital cost of facilities, the time to build them, the failure of early customers and access to downstream equipment. The brief therefore tracks four indicators: tank capacity added, customer bookings, funding awards and facility openings.

Pilot sites first, then demonstration sites, then commercial scale plants are the expected order of adoption.